Covid
Covaxin gets emergency use approval for kids aged 2-18 years
The Subject Expert Committee (SEC) on Covid-19 has granted emergency use approval to Bharat Biotech’s Covaxin for children in the 2-18 years age group.
In September, Hyderabad-based Bharat Biotech had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age and also submitted the trial data to the Drugs and Comptroller General of India (DCGI).
“After detailed deliberation, the committee recommended for grant of market authorization of the vaccine for the age group of 2 to 18 years for restricted use in emergency situation,” the subject expert panel said in a statement.